SCIENTISTS at a leading biotech firm in Halton are celebrating the successful trials of a groundbreaking new vaccine, designed to treat high blood pressure.

The jab, which could reduce the risk of heart attacks and strokes, has already proved a success in the first stage of its clinical programme.

Progress is rapidly being made with the Angiotensin vaccine - a product to regulate blood pressure levels, at Protherics, at The Heath business park in Runcorn.

Experts predict the treatment could be developed to take a slice of the market open to high blood pressure products.

It is unique in its formulations of third-party adjuvants, established to boost the immunity levels of the Angiotensin vaccine to its maximum potential.

Nick Staples, Protherics corporate affairs director, told the Weekly News the finished vaccine could have 'block-busting' effects.

'The adjuvants are there to boost the immune response of our vaccines, and although the trials haven't been completed yet - when we look at our pre-trial data, it does show to have a significant effect on immunity.

'It is likely to benefit people who may forget to take their heart pills regularly, or think they feel well enough not to take their medication as the vaccine lasts for longer.'

Andrew Heath, the chief executive of Protherics, added: 'High blood pressure is a leading cause of stroke and heart attacks.'

The firm announced it has invented the improved formula of the Angiotensin Vaccine, by adding adjuvants components capable of producing an antibody to hypertension.

Previous trials of Angiotensin which took place at Cambridge Hospital have shown to modulate key hormones involved in regulating blood pressure in patients.

Experts have been monitoring the safety of the jabs and strength of antibodies produced.

The vaccine lasts up to five months and is expected to reduce side effects such as dry coughs associated with heart medication.

It is anticipated the first series of trials will be completed later this year, when a further set of trials is expected to be announced.